

## Author Index Volume 9 (1996)

The issue number is given in front of the page numbers.

- International Conference on National Medicinal Drug Policies (1) 47– 59  
Statement of the International Working Group on transparency and accountability in drug regulation (3) 211–217  
Editorial: Time to lift the veil of secrecy (3) 131–132
- Amschler, U., Drug safety regulations of the ‘Drug Commission of the Counties’ (2) 91– 93
- Bankowski, Z., The monitoring of drug safety and reporting of adverse drug reactions (2) 115–120  
Bardelay, D., An ISDB survey to assess the degree of transparency of drug regulatory agencies (3) 151–155  
Beckmann, J., Drug safety regulations and strategies of the German authority for medicinal products (2) 75– 81  
Beppu, H., The case of contaminated blood products in Japan (3) 157–159  
Bertelsmann, A., Statutory regulations governing the reporting of adverse reactions (2) 101–106  
Bixler, E.O., see Kales, A. (1) 7– 27
- Dinnendahl, V., Drug safety regulations of the ‘Drug Commission of the German Pharmacists’ (2) 87– 90  
Dukes, G., Editorial: Drug safety: can more be done? (2) 71– 73  
Dukes, M.N.G., Contaminated Human Growth hormone as a cause of Creutzfeldt–Jakob disease (1) 41– 46  
Dukes, M.N.G., Drug regulation and the tradition of secrecy (3) 143–149
- Helsing, E., Health promoting policies: strong, weak, . . . , and sometimes harmful? (1) 1– 6  
Hemminki, E., see Ollila, E. (3) 161–172  
Herxheimer, A., Side effects: freedom of information and the communication of doubt (3) 201–210  
Hodgkin, C., International harmonisation – the need for transparency (3) 195–199
- Jensen, L.P., see Levi, N. (1) 29– 31
- Kales, A., A.N. Vgontzas and E.O. Bixler, A reassessment of triazolam (1) 7– 27
- Lee, R., Drug safety regulations in the CPMP (2) 107–113  
Levi, N., L.P. Jensen and T.V. Schroeder, Audit of the Danish national vascular database (1) 29– 31
- Medawar, C., Secrecy and medicines (3) 133–141  
Munter, K.-H., Drug safety regulations of the ‘Drug Commission of the German Physicians’ (2) 83– 86
- Ollila, E. and E. Hemminki, Secrecy in drug regulation (3) 161–172
- Razak, D.A., Access to regulatory information in Malaysia – a preliminary study (3) 179–186

- Sammut, M. and C. Savona-Ventura, Petrol lead in a small island environment (1) 33– 40  
Savona-Ventura, C., see Sammut, M. (1) 33– 40  
Schroeder, T.V., see Levi, N. (1) 29– 31
- Tempelaar, A.F., Risk and safety in practice (1) 65– 69  
Tempelaar, A.F., Safety and risk in practice (2) 121–129  
Thiele, A., The German 'Graduated Plan' – criteria, administration, regulations (2) 95–100
- Vgontzas, A.N., see Kales, A. (1) 7– 27  
Vrhovac, B., Access to information on drug regulation in the countries of Central and Eastern Europe (3) 173–178
- Weerasuriya, K., Globalisation of drug regulation and drug regulators in developing countries (3) 187–193